Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech...

* Reuters is not responsible for the content in this press release.

Tue Mar 24, 2009 5:48pm EDT

Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the
Biotech Industry Conference

LIVE AUDIO WEBCAST THURSDAY, APRIL 2, 2009

SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief
Executive Officer of Neurocrine Biosciences will present at BioCentury
Publications, Inc. 16th Annual Future Leaders in the Biotech Industry
Conference in New York. 

The live presentation takes place Thursday, April 2, 2009 at 2:30 p.m. Eastern
Time (ET)/11:30 a.m. Pacific Time (PT).  The presentation will be
simultaneously webcast and may be accessed on the Company's website at
http://www.neurocrine.com. 

If you are unable to attend the webcast and would like further information on
this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the
website approximately 5 minutes prior to the presentation to download or
install any necessary software.  A replay of the presentation will be
available approximately one hour after the conclusion of the live event and
will be archived on the website for two weeks.

About Neurocrine
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on
neurological and endocrine diseases and disorders.  Our product candidates
address some of the largest pharmaceutical markets in the world including
endometriosis, anxiety, depression, pain, diabetes, benign prostatic
hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and
endocrine related diseases and disorders.  Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the internet at
http://www.neurocrine.com





SOURCE  Neurocrine Biosciences, Inc.

Claudia Woodworth of Neurocrine Biosciences, Inc., +1-858-617-7600
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.